## **Supporting Information**

# Efficient Synthesis of Chiral Cyclic Acetals by Metal and Brønsted Acid Co-Catalyzed Entioselective Four-component

## **Cascade Reactions**

## Lin Qiu, Xin Guo, Chaoqun Ma, Huang Qiu, Shunying Liu\*,

### Liping Yang and Wenhao Hu\*

Shanghai Engineering Research Center of Molecular Therapeutics and New Drug Development, East China Normal University, Shanghai, China; Fax: 86-21-62221237; E-mail: syliu@sist.ecnu.edu.cn; whu@chem.ecnu.edu.cn.

## Contents

#### pages

General Considerations	S2
Synthesis of Substrates	S2
References	S2
General procedure for four-component reactions of aryldiazoacetates 1 w amines 2 and methyl 3-(2-formylphenoxy)propenoates 3	ith water, 83
Optimization for the four-component cascade reaction	S4
Proposed reaction pathway for the four-component cascade reaction	S5
Crystal data of <b>6d</b>	S6
Characterization Data of Products	
NMR spectra for the Compounds	
Chiral HPLC analysis figures of the Products	S34-S52

#### **General Considerations**:

All moisture sensitive reactions were performed under an argon atmosphere in a well-dried reaction flask. Dichloromethane (CH<sub>2</sub>Cl<sub>2</sub>), 1, 2-dichloroenthene [(CH<sub>2</sub>Cl)<sub>2</sub>] and chloroform (CHCl<sub>3</sub>) were freshly distilled over calcium hydride, toluene from sodium benzophenone ketyl, respectively, prior to use. Solvents for the column chromatography were distilled before use. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Brucker-400 MHz spectrometer. Chemical shifts are reported in ppm relative to the internal standard tetramethylsilane ( $\delta = 0$  ppm) for <sup>1</sup>H NMR and deuteriochloroform ( $\delta = 77.00$  ppm) for <sup>13</sup>C NMR spectroscopy. HRMS spectra were recorded on a Bruker micrOTOF II instrument. HPLC analysis was performed on Waters-Breeze (2487 Dual Absorbance Detector and 1525 Binary HPLC Pump) & Shimadzu (SPD-20AV UV-VIS Detector and LC-20AT Liquid Chromatograph Pump). Chiralpak IA and OD-H was purchased from Daicel Chemical Industries, LTD. The racemic standards used in HPLC studies were prepared according to the general procedure by using a racemic BINOL derivatived phosphoric acid catalyst.

#### **Synthesis of Substrates:**

Various aryl diazo compounds 1 were prepared by the treatment of corresponding arylacetate with *p*-acetamidobenzenesulfonyl azide (*p*-ABSA) in the presence of DBU following the general procedure.<sup>1</sup> Substrates 3 were synthesized following literature procedure.<sup>2</sup> Others were purchased from commercial suppliers and used without further purification.

#### **References:**

M. P. Doyle, M. A. McKervey and T. Ye, *Modern Catalytic Methods for Organic Synthesis with Diazo Compounds*, Wiley, New York, 1998.
D. H. T. Phan, B. Kim and V. M. Dong, *J. Am. Chem. Soc.* 2009, **131**, 15608.

General procedure for four-component reactions of aryldiazoacetates 1 with water, amines 2 and methyl 3-(2-formylphenoxy)propenoates 3:



To a stirred solution of  $Rh_2(OAc)_4$  (3.3 mg, 1 mol%), the chiral phosphoric acid 4 (5.0 mol%), arylamine 2 (0.12 mmol), and methyl 3-(2-formylphenoxy)propenoates 3 (0.10 mmol, 1.0 eq), 4 Å MS (100 mg) in 1.5 mL dichloromethane (0.05% (w/w) water content) at room temperature for 30 min, then added diazo compounds 1(0.15 mmol) in dichloromethane (0.5 ml) over 1 hour via a syringe pump. After completion of the addition, the reaction mixture was stirred for another 0.5 h, then passed through a short flash column of silica gel, after removal of the solvent under reduced pressure, dichloromethane (2.0 mL) was added. This solution was transferred to a reaction tube containing a magnetic stirring bar, and the temperature of the solution was to room temperature, followed by the addition of DBU (0.10 mmol, 1.0 eq). The reaction was detected by TLC until 7 consumed up, and then subjected to <sup>1</sup>H NMR spectroscopic analysis after solvent removal to determine product diastereoselectivity. The crude reaction mixture was purified by column chromatography on silica gel (eluent light petroleum/EtOAc=20:1 to 5:1) to give the pure product **6**.

	CO <sub>2</sub> Me Ar	NH <sub>2</sub>		Ar. NH CO Mo	Si Angel Si	iPh <sub>3</sub>	
	$Ph \wedge N_2 2$	<b>a</b> 1.1 m	ol%Rh <sub>2</sub> (OAc) <sub>4</sub> ,	Ph		0	
	1a + O	5 m	ol% 4, 4AMS			ОН	
	н.о Г	CO <sub>2</sub> Me <sup>2. bas</sup>	se Ai	r=4-BrC₀H₄		iPh <sub>3</sub>	
		<b>3</b> a		6a	(S)-4		
Entry	Solvent	<i>T</i> (°C)	Base (eqv.)	Yield(%) <sup>b</sup>	dr <sup>c</sup>	ee(%) <sup>d</sup>	
1	DCM	25	DBU(0.2)	20	>99:1	91	
2	DCM	25	piperidine(0.2)	<5	nd <sup>e</sup>	nd <sup>e</sup>	
3	DCM	25	TEA(0.2)	<5	nd <sup>e</sup>	nd <sup>e</sup>	
4	DCM	25	DIPEA(0.2)	<5	nd <sup>e</sup>	nd <sup>e</sup>	
5	DCM	25	TFA	0	nd <sup>e</sup>	nd <sup>e</sup>	
6	DCM	40	DBU(0.2)	35	>99:1	91	
7	DCM	0	DBU(0.2)	10	>99:1	92	
8	DCM	25	DBU(1.0)	45	>99:1	91	
9	DCM	25	Na <sub>2</sub> CO <sub>3</sub>	0	nd <sup>e</sup>	nd <sup>e</sup>	
10	DCM	25	$K_2CO_3$	0	nd <sup>e</sup>	nd <sup>e</sup>	
11	DCM	25	NaOH	<5	nd <sup>e</sup>	nd <sup>e</sup>	
12	CHCl <sub>3</sub>	25	DBU(1.0)	47	>99:1	38	
13	DCE	25	DBU(1.0)	35	>99:1	69	
14	Toluene	25	DBU(1.0)	38	>99:1	80	
15 <sup><i>f</i></sup>	DCM	25	DBU(1.0)	23	>99:1	91	
<sup>a</sup> Reaction co	<sup>a</sup> Reaction conditions: 1a/H <sub>2</sub> O/2a/3a was 1.5/0.5/1.2/1.0. <sup>b</sup> Isolated yield of 6a. <sup>c</sup> Determined by <sup>1</sup> H NMR						
spectroscopy of the crude reaction mixture. <sup>d</sup> Determined by chiral HPLC with IC column. <sup>e</sup> nd: not detected. <sup>f</sup> no							
4 ÅMS ad	ded. DBU: 1	, 8-diazabicyc	lo [5.4.0] ur	ndec-7-ene, TH	EA: triethylam	nine, DIPEA: N,	
N-diisopropyle	thylamine, TFA	: trifluoroaceti	c acid.				

Table S1. Optimization for the four-component cascade reaction <sup>a</sup>



Scheme S1. Intramolecular oxy-Michael addition via DBU catalyzed.





Electronic Supplementary Material (ESI) for Chemical Communications This journal is C The Royal Society of Chemistry 2013

### Crystal data of 6d (CCDC: 941071)



Bond precision: (		= 0.0050 A	Wavelength=0.710	Wavelength=0.71073	
Cell: a=11.8142(		b=14.0221(8)	c=15.3593(9)		
	alpha=90	beta=90	gamma=90		
Temperature:	296 К				
	Calcul	lated	Reported		
Volume	2544.4	1(3)	2544.4(3)		
Space group	P 21 2	21 21	P2(1)2(1)2(		
Hall group	P 2ac	2ab	?		
Moiety formu	la C26 H2	23 Br2 N 06	?		
Sum formula	C26 H2	23 Br2 N 06	C26 H23 Br2 N C	)6	
Mr	605.25	5	605.27		
Dx,g cm-3	1.580		1.580		
Z	4		4		
Mu (mm-1)	3.227		3.227		
F000	1216.0	)	1216.0		
F000'	1214.2	29			
h,k,lmax	14,16,	18	14,16,18		
Nref	2539[	4478]	4478		
Tmin,Tmax	0.281,	0.559	0.344,0.594		
Tmin'	0.237				
Correction m	ethod= MULTI-S	CAN			
Data complet	eness= 1.76/1.	00 Theta(ma	x)= 25.010		
R(reflection	us)= 0.0309( 38	26) wR2(r	reflections)= 0.0736( 4478)		
s = 1.025	Npa	ar= 316			

#### **Characterization Data of Products:**

(2S,4R,5R)-methyl5-(4-bromophenylamino)-2-(2-methoxy-2-oxoethyl)-4-phenyl-4,5-dihydrobenzo[d][1,3]dioxepine-4-carboxylate(6a)



Yield: 45%; >95:5 dr; 91% ee; determined by HPLC (Daicel Chirapak IC, flow rate 0.8 mL/min, hexane/isopropanol =50:10, 254 nm, Retention time: tminor = 12.7 min, tmajor = 10.3 min);

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.57 (d, J = 7.5 Hz, 2H), 7.37-7.22 (m, 3H), 7.23 – 7.13 (m, 2H), 7.09 (t, J = 7.6 Hz, 1H), 7.00 (d, J = 7.8 Hz, 3H), 6.87 (d, J = 7.8 Hz, 1H), 6.33 (d, J = 7.9 Hz, 2H), 5.54 (s, 1H), 5.24 (d, J = 10.8 Hz,

1H), 4.83 (d, *J* = 10.8 Hz, 1H), 3.72 (s, 3H), 3.49 (s, 3H), 3.10 (qd, *J* = 15.3, 4.4 Hz, 2H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.79, 168.26, 156.22, 144.30, 136.60, 130.87, 130.62, 129.67, 128.40, 127.45, 127.37, 124.41, 123.41, 120.44, 114.49, 108.38, 99.31, 83.36, 61.74, 51.63, 50.95, 40.42;

ESCI-HRMS Calcd. for C<sub>26</sub>H<sub>24</sub>BrNNaO<sub>6</sub>, [M+Na]<sup>+</sup> 548.0664; Found: 548.0679.





Yield: 43%; >95:5 dr; 95% ee; determined by HPLC (Daicel Chirapak IC, flow rate 0.8 mL/min, hexane/isopropanol =50:10, 254 nm, Retention time: tminor = 8.7 min, tmajor = 10.0 min);

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.44 (d, J = 8.2 Hz, 2H), 7.31 (d, J = 6.9 Hz, 1H, 7.19 (s, 1H), 7.08 (dd, J = 12.0, 8.4 Hz, 3H), 6.99 (dd, J = 11.4, 8.1 Hz, 3H), 6.86 (d, J = 7.8 Hz, 1H), 6.34 (d, J = 8.7 Hz, 2H),

5.65-5.43 (m, 1H), 5.23 (d, J = 10.8 Hz, 1H), 4.82 (d, J = 10.8 Hz, 1H),  $\overline{3.72}$  (s, 3H), 3.49 (s, 3H), 3.09 (qd, J = 15.3, 5.5 Hz, 2H), 2.23 (s, 3H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.94, 168.29, 156.27, 144.39, 137.20, 133.73, 130.89, 130.64, 129.78, 128.36, 128.18, 124.36, 123.36, 120.45, 114.55, 108.37, 99.32, 83.32, 61.70, 51.56, 50.92, 40.47, 20.02;

ESCI-HRMS Calcd. for C<sub>27</sub>H<sub>26</sub>BrNNaO<sub>6</sub>, [M+Na]<sup>+</sup> 562.0820; Found: 562.0836.

#### (2S,4R,5R)-methyl 5-(4-bromophenylamino)-4-(4-chlorophenyl)-2-(2-methoxy-2-oxoethyl)-4,5-dihydrobenzo[d][1,3]dioxepine-4-carboxylate (6c)



Yield: 51%; >95:5 dr; 99% ee; determined by HPLC (Daicel Chirapak IC, flow rate 0.8 mL/min, hexane/isopropanol =50:10, 254 nm, Retention time:  $t_{minor} = 12.7 min$ ,  $t_{major} = 10.5 min$ );

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.51 (d, J = 8.6 Hz, 2H), 7.30 (d, J = 8.3 Hz, 1H), 7.26-7.15 (m, 2H), 7.10 (m, 1H), 7.00 (m, 3H), 6.87 (d, J = 7.9 Hz, 1H), 6.33

(d, J = 8.7 Hz, 2H), 5.52 (dd, J = 6.0, 5.0 Hz, 1H), 5.18 (d, J = 10.6 Hz, 1H), 4.79 (d, J = 10.8 Hz, 1H), 3.73 (s, 3H), 3.51 (s, 3H), 3.09 (qd, J = 15.4, 5.5 Hz, 2H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.53, 168.16, 156.19, 144.15, 195.23, 133.42, 130.85, 130.75, 129.41, 128.55, 127.63, 125.96, 123.51, 120.49, 114.60, 108.75, 99.32, 83.12, 61.89, 51.76, 50.97, 40.41;

ESCI-HRMS Calcd. for C<sub>26</sub>H<sub>23</sub>BrClNNaO<sub>6</sub>, [M+Na]<sup>+</sup> 582.0272; Found: 582.0289.

(2S,4R,5R)-methyl 4-(4-bromophenyl)-5-(4-bromophenylamin)-2-(2-methoxy-2oxoethyl)-4,5-dihydrobenzo[d][1,3]dioxepine-4-carboxylate (6d)



Yield: 47%; >95:5 dr; 96% ee; determined by HPLC (Daicel Chirapak IC, flow rate 0.8 mL/min, hexane/isopropanol =50:10, 254 nm, Retention time: tminor = 13.4 min, tmajor = 10.6 min);

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.45 (d, J = 8.7 Hz, 2H), 7.39 (d, J = 8.7 Hz, 2H), 7.30 (d, J = 7.4 Hz, 1H), 7.21-7.06 (m, 1H), 7.00 (m, 3H), 6.87 (d, J = 7.9 Hz, 1H), 6.33 (d, J = 8.7 Hz, 2H), 5.52 (dd, J = 6.1,

4.9 Hz, 1H), 5.18 (d, *J* = 11.1 Hz, 1H), 4.79 (d, *J* = 11.1 Hz, 1H), 3.72 (s, 3H), 3.51 (s, 3H), 3.09 (qd, *J* = 15.4, 5.5 Hz, 2H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.46, 168.15, 156.19, 144.14, 135.90, 130.86, 130.75, 130.60, 129.38, 128.56, 126.28, 123.52, 121.67, 120.49, 114.62, 108.78, 99.32, 83.16, 61.84, 51.77, 50.97, 40.41;

ESCI-HRMS Calcd. for C<sub>26</sub>H<sub>23</sub>Br<sub>2</sub>NNaO<sub>6</sub>. [M+Na]<sup>+</sup> 625.9775; Found: 625.9784.

(2S,4R,5R)-methyl 4-(3-bromophenyl)-5-(4-bromophenylamino)-2-(2-methoxy-2-oxoethyl)-4,5-dihydrobenzo[d][1,3]dioxepine-4-carboxylate(6e)



Yield: 46%; >95:5 dr; 98% ee; determined by HPLC (Daicel Chirapak IC, flow rate 0.8 mL/min, hexane/isopropanol =50:10, 254 nm, Retention time:  $t_{minor} = 13.2 \text{ min}, t_{major} = 10.6 \text{ min}$ );

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.75 (s, 1H), 7.49 (d, *J* = 8.1 Hz, 1H), 7.32 (dd, *J* = 15.0, 7.7 Hz, 2H), 7.12 (dd, *J* = 18.2, 8.0 Hz, 2H), 7.00 (dd, *J* = 12.7, 8.1 Hz, 3H), 6.87 (d, *J* = 7.9 Hz, 1H), 6.34 (d, *J* = 8.7 Hz, 2H),

5.57-5.44 (m, 1H), 5.17 (d, *J* = 11.1 Hz, 1H), 4.78 (d, *J* = 11.1 Hz, 1H), 3.74 (s, 3H), 3.52 (s, 3H), 3.11 (qd, *J* = 15.4, 5.5 Hz, 2H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.37, 168.18, 156.15, 144.16, 138.98, 130.87, 130.71, 130.51, 129.37, 128.94, 128.56, 127.96, 123.55, 122.83, 121.70, 120.48, 114.71, 108.79, 99.36, 83.02, 62.19, 51.84, 51.01, 40.41;

ESCI-HRMS Calcd. for C<sub>26</sub>H<sub>23</sub>Br<sub>2</sub>NNaO<sub>6</sub>, [M+Na]<sup>+</sup> 625.9775; Found: 625.9784.

## (2S,4R,5R)-methyl 5-(4-bromophenylamino)-2-(2-methoxy-2-oxoethyl)-4-(2-methoxyphenyl)-4,5-dihydrobenzo[d][1,3]dioxepine-4-carboxylate (6f)



1H), 5.37 (t, 
$$J = 5.4$$
 Hz, 1H), 4.61 (d,  $J = 9.9$  Hz, 1H),  
3.78 (s, 3H), 3.67 (s, 3H), 3.53 (s, 3H), 3.02 (qd,  $J = 15.4$ , 5.4 Hz, 2H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.65, 168.15, 154.54, 154.36, 144.82, 131.12, 130.45, 128.49, 127.61, 127.49, 125.60, 123.25, 119.93, 114.20, 110.15, 107.80, 98.17, 81.80, 59.93, 54.63, 51.32, 50.92, 40.61;

ESCI-HRMS Calcd. for C<sub>27</sub>H<sub>26</sub>BrNNaO<sub>7</sub>, [M+Na]<sup>+</sup> 578.0779; Found: 578.0785.

#### (2S,4R,5R)-methyl 5-(4-chlorophenylamino)-2-(2-methoxy-2-oxoethyl)-4-phenyl-4,5-dihydrobenzo[d][1,3]dioxepine-4-carboxylate(6g)



Yield: 46%; >95:5 dr; 90% ee; determined by HPLC (Daicel Chirapak IC, flow rate 0.8 mL/min, hexane/isopropanol =50:10, 254 nm, Retention time: tminor = 12.0 min, tmajor = 9.7 min);

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.58 (d, J = 7.8 Hz, 2H), 7.36-7.24 (m, 1H), 7.24–7.14 (m, 2H), 7.09 (t, J = 7.4 Hz, 1H), 6.99 (t, J = 7.4 Hz, 1H), 6.91-6.79 (m, 3H), 6.37 (d, J= 8.7 Hz, 2H), 5.54 (dd, J = 6.2, 4.9 Hz, 1H), 5.24 (d, J =

10.9 Hz, 1H), 4.80 (d, J = 10.9 Hz, 1H), 3.73 (s, 3H), 3.50 (s, 3H), 3.10 (qd, J = 15.4, 5.5 Hz, 2H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.84, 168.27, 156.25, 143.92, 136.67, 130.87, 129.78, 128.38, 127.77, 127.44, 127.36, 124.44, 123.40, 121.38, 120.44, 114.11, 99.34, 83.44, 62.08, 51.62, 50.94, 40.46;

ESCI-HRMS Calcd. for C<sub>26</sub>H<sub>24</sub>ClNNaO<sub>6</sub>, [M+Na]<sup>+</sup> 504.162; Found: 504.1184.

## (2S,4R,5R)-methyl 5-(3-chlorophenylamino)-2-(2-methoxy-2-oxoethyl)-4-phenyl-4,5-dihydrobenzo[d][1,3]dioxepine-4-carboxylate(6h)



Yield: 42%; >95:5 dr; 90% ee; determined by HPLC (Daicel Chirapak IC, flow rate 0.8 mL/min, hexane/isopropanol =50:10, 254 nm, Retention time: tminor = 9.7 min, tmajor = 7.6 min);

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.58 (d, J = 7.5 Hz, 2H), 7.36 (d, J = 7.3 Hz, 1H), 7.32-7.14 (m, 3H), 7.14-6.95 (m, 2H), 6.95-6.76 (m, 2H), 6.45 (d, J = 7.9 Hz, 2H), 6.31 (d, J = 8.5 Hz, 1H), 5.62-5.47 (m, 1H), 5.26 (d, J = 10.8 Hz, 1H), 4.89 (d, J = 10.8 Hz, 1H), 3.74 (s, 3H), 3.51 (s, 3H), 3.11 (qd, J = 15.4, 5.5

Hz, 2H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  168.75, 168.27, 156.23, 146.40, 136.51, 133.57, 130.85, 129.61, 128.88, 128.42, 127.46, 127.39, 124.40, 123.47, 120.47, 116.58, 112.49, 111.04, 99.29, 98.94, 83.35, 61.49, 51.66, 50.97, 40.41;

ESCI-HRMS Calcd. for  $C_{26}H_{24}CINNaO_6$ ,  $[M+Na]^+$  504.1162; Found: 504.1145.

(2S,4R,5R)-methyl 5-(3,4-dichlorophenylamino)-2-(2-methoxy-2-oxoethyl)-4phenyl-4,5-dihydrobenzo[d][1,3]dioxepine-4-carboxylate(6i)



Yield: 52%; >95:5 dr; 92% ee; determined by HPLC (Daicel Chirapak IC, flow te 0.8 mL/min, hexane/isopropanol =50:10, 254 nm, Retention time:  $t_{minor}$ = 20.3 min,  $t_{major}$  = 17.2 min);

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.57 (d, J = 7.9 Hz, 2H), 7.39-7.16 (m, 4H), 7.08 (dd, J = 31.2, 7.5 Hz, 2H), 6.91 (dd, J = 17.2, 8.3 Hz, 2H), 6.52 (s, 1H), 6.27 (d, J = 8.6 Hz, 1H), 5.54 (t, J = 5.2 Hz, 1H), 5.20 (d, J = 10.7 Hz, 1H), 4.90 (d, J = 10.7 Hz, 1H), 3.73 (s, 3H), 3.51 (s, 3H), 3.10 (qd, J =

15.5, 5.4 Hz, 2H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.64, 168.22, 156.19, 144.81, 136.42, 131.43, 130.81, 129.38, 129.31, 128.59, 127.51, 127.49, 124.35, 123.55, 120.55, 119.21, 113.97, 112.41, 99.34, 83.28, 61.85, 51.69, 50.98, 40.39;

ESCI-HRMS Calcd. for C<sub>26</sub>H<sub>23</sub>Cl<sub>2</sub>NNaO<sub>6</sub>. [M+Na]<sup>+</sup> 538.0781; Found: 538.0795.

(2S,4R,5R)-methyl 5-(3,4-difluorophenylamino)-2-(2-methoxy-2-oxoethyl)-4phenyl-4,5-dihydrobenzo[d][1,3]dioxepine-4-carboxylate(6j)



Yield: 53%; >95:5 dr; 94% ee; determined by HPLC (Daicel Chirapak IC, flow rate 0.8 mL/min, hexane/isopropanol =50:10, 254 nm, Retention time: tminor = 9.6 min, tmajor = 12.0 min);

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.58 (d, J = 7.5 Hz, 2H), 7.36-7.21 (m, 4H), 7.06 (m, 2H), 6.89 (d, J = 7.8 Hz, 1H), 6.69 (q, J = 9.2 Hz, 1H), 6.32-6.15 (m, 1H), 6.09 (d, J = 8.6 Hz, 1H), 5.61-5.47 (m, 1H), 5.15 (d, J = 10.9 Hz, 1H), 4.75 (d, J = 10.9 Hz, 1H), 3.73 (s, 3H), 3.51 (s, 3H), 3.11 (qd, J =

15.4, 5.5 Hz, 2H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.72, 168.24, 156.15, 136.55, 130.83, 129.56, 128.47, 127.47, 127.40, 124.35, 123.48, 120.45, 116.20, 116.02, 108.45, 101.86, 101.65, 99.32, 83.33, 62.77, 51.67, 50.97, 40.40;

ESCI-HRMS Calcd. for C<sub>26</sub>H<sub>23</sub> F<sub>2</sub>NNaO<sub>6</sub>, [M+Na]<sup>+</sup> 506.1371; Found: 506.1376.

NH CO<sub>2</sub>Me

6k

CO<sub>2</sub>Me

#### (2S,4R,5R)-methyl 5-(3,5-difluorophenylamino)-2-(2-methoxy-2-oxoethyl)-4phenyl-4,5-dihydrobenzo[d][1,3]dioxepine-4-carboxylate(6k)

Yield: 43%; >95:5 dr; 93% ee; determined by HPLC (Daicel Chirapak IC, flow rate 0.8 mL/min, hexane/isopropanol =50:10, 254 nm, Retention time: tminor = 9.4 min, tmajor = 7.8 min);

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ 7.56 (d, J = 7.5 Hz, 2H), 7.36 (d, J = 7.0 Hz, 1H), 7.32-7.17 (m, 5H), 7.13 (d, J = 7.4 Hz, 1H), 7.05 (d, J = 7.3 Hz, 1H), 6.90 (d, J = 7.8 Hz, 1H), 5.92 (t, J = 10.8 Hz, 3H), 5.59-5.48 (m, 1H), 5.20 (d, J = 10.6 Hz,

1H), 5.05 (d, *J* = 10.6 Hz, 1H), 3.74 (s, 3H), 3.51 (s, 3H), 3.11 (qd, *J* = 15.5, 5.5 Hz, 2H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.63, 168.21, 156.23, 146.39, 146.29, 136.43, 132.05, 130.81, 129.41, 128.59, 127.52, 124.36, 123.56, 120.55, 110.04, 100.58, 100.32, 99.35, 83.28, 61.82, 51.68, 50.96, 40.40;

ESCI-HRMS Calcd. for C<sub>26</sub>H<sub>23</sub> F<sub>2</sub>NNaO<sub>6</sub>, [M+Na]<sup>+</sup> 506.1371; Found: 506.1386.

#### (2S,4R,5R)-methyl 5-(4-bromo-3-fluorophenylamino)-2-(2-methoxy-2-oxoethyl)-4-phenyl-4,5-dihydrobenzo[d][1,3]dioxepine-4-carboxylate(6l)



Yield: 41%; >95:5 dr; 88% ee; determined by HPLC (Daicel Chirapak IC, flow rate 0.8 mL/min, hexane/isopropanol =50:10, 254 nm, Retention time: tminor = 13.2 min, tmajor = 11.1 min);

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.57 (d, J = 7.9 Hz, 2H), 7.38-7.16 (m, 4H), 7.08 (m, 2H), 6.91 (dd, J = 17.2, 8.3 Hz, 2H), 6.52 (s, 1H), 6.27 (d, J = 8.6 Hz, 1H), 5.54 (t, J = 5.2Hz, 1H), 5.20 (d, J = 10.7 Hz, 1H), 4.90 (d, J = 10.7 Hz, 1H), 3.73 (s, 3H), 3.51 (s, 3H), 3.10 (qd, J = 15.5, 5.4 Hz,

2H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.64, 168.22, 156.19, 144.81, 136.42, 131.43, 130.81, 129.38, 129.31, 128.59, 127.51, 127.49, 124.35, 123.55, 20.55, 119.21, 113.97, 112.41, 99.34, 83.28, 61.85, 51.69, 50.98, 40.39;

ESCI-HRMS Calcd. for C<sub>26</sub>H<sub>23</sub>BrFNNaO<sub>6</sub>, [M+Na]<sup>+</sup> 566.0573; Found: 566.0585.

#### (2S,4R,5R)-methyl 5-(4-bromophenylamino)-7-methoxy-2-(2-methoxy-2oxoethyl)-4-phenyl-4,5-dihydrobenzo[d][1,3]dioxepine-4-carboxylate(6l)



Yield: 47%; >95:5 dr; 76% ee; determined by HPLC (Daicel Chirapak IC, flow rate 0.8 mL/min, hexane/isopropanol =50:10, 254 nm, Retention time: tminor = 15.6 min, tmajor = 16.6 min);

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.57 (d, J = 7.4 Hz, 2H), 7.27 (t, J = 7.1 Hz, 2H), 7.23-7.15 (m, 3H), 7.02 (d, J = 7.7 Hz, 2H), 6.89-6.73 (m, 2H), 6.60 (d, J = 8.7 Hz, 1H), 6.35 (d, J = 7.6 Hz, 2H), 5.51 (s, 1H), 5.17 (d, J = 10.9 Hz, 1H), 4.83 (d, *J* = 10.9 Hz, 1H), 3.73 (s, 3H), 3.70 (s, 3H), 3.52 (s, 3H), 3.07 (dd, *J* = 16.5, 11.5 Hz, 2H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.78, 168.34, 154.89, 149.97, 144.30, 136.70, 130.65, 127.44, 127.36, 124.41, 120.94, 116.56, 114.55, 112.41, 108.42, 99.52, 83.43, 61.78, 54.61, 51.66, 50.94, 40.35;

ESCI-HRMS Calcd. for C<sub>27</sub>H<sub>26</sub>BrNNaO<sub>7</sub>, [M+Na]<sup>+</sup> 578.0772 Found: 578.0785.

(2S,4R,5R)-methyl 5-(4-bromophenylamino)-9-methoxy-2-(2-methoxy-2oxoethyl)-4-phenyl-4,5-dihydrobenzo[d][1,3]dioxepine-4-carboxylate(6m)



4.88 (d, *J* = 11.0 Hz, 1H), 3.73 (s, 3H), 3.71 (s, 3H), 3.51 (s, 3H), 3.14 (qd, *J* = 14.3, 5.1 Hz, 2H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.81, 168.10, 150.50, 145.23, 144.26, 136.65, 131.10, 130.58, 127.44, 127.36, 124.44, 123.55, 122.40, 114.53, 111.00, 108.32, 99.97, 83.29, 61.53, 54.87, 51.61, 51.01, 40.88;

ESCI-HRMS Calcd. for C<sub>27</sub>H<sub>26</sub>BrNNaO<sub>7</sub>, [M+Na]<sup>+</sup> 578.0769; Found: 578.0785.

(2S,4R,5R)-methyl 5-(4-bromophenylamino)-7-chloro-2-(2-methoxy-2-oxoethyl)-4-phenyl-4,5-dihydrobenzo[d][1,3]dioxepine-4-carboxylate(60)



Yield: 51%; >95:5 dr; 98% ee; determined by HPLC (Daicel Chirapak IC, flow rate 0.8 mL/min, hexane/isopropanol =50:10, 254 nm, Retention time: tminor = 9.4 min, tmajor = 10.6 min);

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.54 (d, J = 7.4 Hz, 2H), 7.36 – 7.12 (m, 6H), 7.04 (t, J = 9.1 Hz, 3H), 6.82 (d, J = 8.3 Hz, 1H), 6.32 (d, J = 7.8 Hz, 2H), 5.49 (s, 1H), 5.17 (d, J = 10.9 Hz, 1H), 4.79 (d, J = 10.8 Hz, 1H), 3.72 (s, 3H),

3.54 (s, 3H), 3.19 – 2.97 (m, 2H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.57, 168.15, 154.76, 143.92, 136.21, 131.51, 130.78, 130.39, 128.61, 128.31, 127.52, 124.28, 121.83, 114.44, 108.76, 99.54, 83.38, 61.48, 51.83, 51.01, 40.22;

ESCI-HRMS Calcd. for C<sub>26</sub>H<sub>23</sub>BrClNNaO<sub>6</sub>, [M+Na]<sup>+</sup> 582.0287; Found: 582.0289.

#### (2S,4R,5R)-methyl 7-bromo-5-(4-bromophenylamino)-2-(2-methoxy-2-oxoethyl)-4-phenyl-4,5-dihydrobenzo[d][1,3]dioxepine-4-carboxylate(6p)



Yield: 53%; >95:5 dr; 97% ee; determined by HPLC (Daicel Chirapak IC, flow rate 0.8 mL/min, hexane/isopropanol =50:10, 254 nm, Retention time: tminor = 9.7 min, tmajor = 11.3 min);

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.54 (d, J = 7.4 Hz, 2H), 7.47 (s, 1H), 7.32-7.12 (m, 5H), 7.03 (d, J = 7.6 Hz, 2H), 6.76 (d, J = 8.4 Hz, 1H), 6.32 (d, J = 7.7 Hz, 2H), 5.49 (s, 1H), 5.17 (d, J = 10.8 Hz, 1H), 4.79 (d, J = 10.8 Hz, 1H),

3.72 (s, 3H), 3.54 (s, 3H), 3.18 – 2.98 (m, 2H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 168.54, 168.13, 155.29, 143.89, 136.18, 133.28, 131.95, 131.30, 130.79, 127.52, 124.27, 122.26, 116.30, 114.40, 108.75, 99.49, 83.37, 61.41, 51.84, 51.02, 40.22;

ESCI-HRMS Calcd. for C<sub>26</sub>H<sub>23</sub>Br<sub>2</sub>NNaO<sub>6</sub>. [M+Na]<sup>+</sup> 625.9767; Found: 625.9784.

#### (2S,4R,5R)-methyl 5-(4-bromophenylamino)-7-tert-butyl-2-(2-methoxy-2oxoethyl)-4-phenyl-4,5-dihydrobenzo[d][1,3]dioxepine-4-carboxylatg(6q)



Yield: 42%; >95:5 dr; 97% ee; determined by HPLC (Daicel Chirapak OD-H, flow rate 0.8 mL/min, hexane/isopropanol =50:10, 254 nm, Retention time: tminor = 8.9 min, tmajor = 10.4 min.);

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.58 (d, J = 7.3 Hz, 2H), 7.36-7.14 (m, 4H), 7.04 (dd, J = 30.5, 8.1 Hz, 4H), 6.77 (d, J = 8.2 Hz, 1H), 6.35 (d, J = 7.7 Hz, 2H), 5.58 (s, 1H), 5.24 (d, J = 10.8 Hz, 1H), 4.86 (d, J = 10.7 Hz, 1H), 3.72

(s, 3H), 3.48 (s, 3H), 3.19-2.98 (m, 2H), 1.23 (s, 9H); <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)  $\delta$  168.61, 168.31, 153.96, 145.91, 144.38, 136.67, 130.50, 128.68, 128.37, 127.42, 127.34, 124.92, 124.56, 119.60, 114.47, 108.19, 99.16, 83.28, 61.68, 51.45, 50.92, 40.43, 33.22, 30.34;

ESCI-HRMS Calcd. for C<sub>30</sub>H<sub>32</sub>BrNNaO<sub>6</sub>, [M+Na]<sup>+</sup>604.1294; Found: 604.1305.

#### (E)-methyl 3-(2-((1R,2R)-1-(3,4-dichlorophenylamino)-2-hydroxy-3-methoxy-3-oxo-2-phenylpropyl)phenoxy)acrylate(7i)



Yield: 65%; 90:10; dr; 92% ee; determined by HPLC (Daicel Chirapak IC, flow rate 0.8 mL/min, hexane/isopropanol =50:10, 254 nm, Retention time:  $t_{minor} = 8.6 min, t_{major} = 10.9 min.$ );

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ 7.83 (d, J = 12.2 Hz, 1H), 7.69 (dd, J = 12.9, 7.8 Hz, 3H), 7.37 (t, J = 7.5 Hz, 2H), 7.34 – 7.27 (m, 2H), 7.16 (t, J = 7.6 Hz, 1H), 7.01 (dd, J

= 14.7, 8.5 Hz, 3H), 6.54 (d, J = 2.6 Hz, 1H), 6.27 (dd, J = 8.8, 2.6 Hz, 1H), 5.84 (d, J

= 12.2 Hz, 1H), 5.65 (d, *J* = 9.3 Hz, 1H), 4.75 (d, *J* = 9.3 Hz, 1H), 4.18 (s, 1H), 3.78 (s, 3H), 3.56 (s, 3H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 172.22, 166.24, 157.73, 152.89, 144.77, 137.66, 131.64, 129.44, 128.92, 127.45, 127.39, 127.12, 125.11, 124.52, 119.22, 116.00, 113.44, 111.96, 102.06, 79.60, 53.62, 52.74, 50.50;

ESCI-HRMS Calcd. for C<sub>26</sub>H<sub>23</sub>Cl<sub>2</sub>NNaO<sub>6</sub>, [M+Na]<sup>+</sup> 538.0779; Found: 538.0795.

(E)-methyl 3-(2-((18,2R)-1-(3,4-dichlorophenylamino)-2-hydroxy-3-methoxy-3-oxo-2-phenylpropyl)phenoxy)acrylate(7i')



0% ee; determined by HPLC (Daicel Chirapak IC, flow rate 0.8 mL/min, hexane/isopropanol =50:10, 254 nm, Retention time: t = 10.9 min,  $t_{major} = 17.7$  min.);

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  7.49 (dd, J = 7.7, 1.5 Hz, 1H), 7.41 – 7.24 (m, 3H), 7.03 (ddd, J = 23.6, 13.9, 5.0 Hz, 8H), 6.69 (d, J = 2.6 Hz, 1H), 6.56 (dd, J = 8.0, 1.0 Hz, 1H), 6.41 (dd, J = 8.7, 2.6 Hz, 1H), 5.61 (d, J =

10.8 Hz, 1H), 5.55 (d, *J* = 12.2 Hz, 1H), 4.90 (d, *J* = 10.9 Hz, 1H), 4.07 (d, *J* = 0.7 Hz, 1H), 3.80 (s, 3H), 3.70 (s, 3H);

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 173.34, 166.26, 157.78, 153.01, 144.67, 136.55, 131.75, 129.57, 128.43, 128.20, 127.20, 127.00, 126.27, 124.74, 123.83, 119.92, 115.37, 114.49, 112.68, 101.75, 80.47, 52.99, 52.40, 50.34;

ESCI-HRMS Calcd. for C<sub>26</sub>H<sub>23</sub>Cl<sub>2</sub>NNaO<sub>6</sub>, [M+Na]<sup>+</sup> 538.0779; Found: 538.0786.



#### NMR spectra for the Compounds:











































Chiral HPLC analysis figures of the products





"	NKED #31-3(mm)	·+m()((((())))))	
1	8.17	13767.55	47.7755
2	9.75	15049.62	52.2245
合计		28817.17	100



合计 20760.70 100



#	保留时间(min)	峰面积(mv.sec)	面积百分比(%)
1 2	10.28 12.52	1972.72 2114.31	48.2678 51.7322
合计		4087.03	100



	m		**##1//(IIIV.500)	
	1	10.51	3450.05	99.4383
	2	12.72	19.49	0.5617
合	计		3469.54	100





"	No Ed # 1 1-3 (mm)	ч+ш-//(шч.50с)	
1	10.60	4010.70	97.7829
2	13.41	90.94	2.2171
合计		4101.64	100





	NKE 11-1(mm)	~+m+//(m+.000)	
1	10.59	2732.24	98.9667
2	13.19	28.53	1.0333
合计		2760.77	100



#	保留时间(min)	峰面积(mv.sec)	面积百分比(%)
1 2	8.08 9.25	1969.18 1927.72	50.5320 49.4680
合计		3896.90	100



1	8.11	425.86	2.5756	
2	9.28	16108.69	97.4244	
合计		16534.56	100	





#	保留时间(min)	峰面积(mv.sec)	面积百分比(%)
1	9.75	8738.85	94.7629
2	12.01	482.95	5.2371
合计		9221.80	100



#	保留时间(min)	峰囬枳(mv.sec)	回积白分比(%)
1	7.77	7035.74	50.9997
2	9.90	6759.91	49.0003
合计		13795.65	100



#	保留时间(min)	峰面积(mv.sec)	面积百分比(%)
1	7.61	12469.24	95.0751
2	9.66	645.91	4.9249
合计		13115.15	100









		, , , ,	
1	9.06	283.27	3.1836
2	11.98	8614.37	96.8164
合计		8897.64	100



#	保留时间(min)	峰面积(mv.sec)	面积百分比(%)
1 2	6.92 8.18	7752.94 6959.36	52.6970 47.3030
合计		14712.30	100



#	保留时间(min)	峰面积(mv.sec)	面积百分比(%)
1	7.76	18795.30	96.3368
2	9.38	714.68	3.6632
21.		10500.00	400

合计 100 19509.98



#	保留时间(min)	峰囬枳(mv.sec)	<b></b> 国积白分比(%)
1	10.82	6939.82	51.9418
2	12.97	6420.96	48.0582
合计		13360.78	100



#	保留时间(min)	峰面积(mv.sec)	面积百分比(%)	
1	11.07	7766.95	94.1366	
2	13.24	483.77	5.8634	
合计		8250.72	100	_

合计

7533.50





	Neter et les (min)	-+ m () ((m .000)	m // H // H // H
1	15.60	1263.52	11.5381
2	16.56	9687.28	88.4619
合计		10950.80	100



#	保留时间(min)	峰面积(mv.sec)	面积百分比(%)
1 2	12.89 17.33	5041.34 4974.05	50.3360 49.6640
合计		10015.39	100







#	保留时间(min)	峰面积(mv.sec)	面积百分比(%)
1	9.40	83.34	0.8123
2	10.60	10176.01	99.1877
合计		10259.35	100



#	保留时间(min)	峰面积(mv.sec)	面积百分比(%)
1	10.49	6089.71	48.7819
2	11.63	6393.82	51.2181
合计		12483.53	100



1	9.66	84.13	1.0849	
2	11.28	7670.81	98.9151	
合计		7754.94	100	

2 合计



保留时间(min)	峰面积(mv.sec)	面积百分比(%)	
7.34	11525.21	50.4126	
9.61	11336.56	49.5874	
	22861.77	100	



合计 9809.91 100



	,		
1	8.66	15304.23	50.7736
2	10.91	14837.89	49.2264
合计		30142.11	100



合计 26569.60 100



	#	保留时间(min)	峰面积(mv.sec)	面积百分比(%)
ſ	1	11.01	8012.69	50.3741
	2	17.90	7893.67	49.6259
	合计		15906.36	100